(VIANEWS) – Shares of GENEURO (CAC 40: GNRO.PA) fell by a staggering 17.86% in 5 sessions from €2.8 to €2.30 at 14:05 EST on Thursday, after five sequential sessions in a row of losses. CAC 40 is sliding 0.28% to €7,110.96, after three consecutive sessions in a row of gains.
About GENEURO
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Earnings Per Share
As for profitability, GENEURO has a trailing twelve months EPS of €-0.45.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENEURO’s stock is considered to be overbought (>=80).
More news about GENEURO (GNRO.PA).
